Navigation Links
CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
Date:3/29/2009

is in line with other marketed statins.

IMPORTANT SAFETY INFORMATION:

CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in adult patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not approved to prevent cardiovascular morbidity and mortality.

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.

Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).

CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age Greater Than or Equal to 65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.

Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and perio
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
7. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
8. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
9. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
10. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
11. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 ... convened in Boston on July ... in an effort to more fully exploit the potential ... applied to brain diseases. "As an established ... a responsibility to assume a leadership role - in ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, Inc., ... treatment of cancer, today announced that Rachel ... company,s Board of Directors, has been appointed chief ... Eli Lilly and AstraZeneca, and also oversaw clinical ... checkpoint inhibitor, at Bristol-Myers Squibb and the development ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015 Oryzon today ... Renshaw 17th Annual Global Investment Conference in New ... ORYZON will be represented by President and CEO Carlos ... Dr. Buesa will present this information on Thursday September 10, ... Floor).  The company is completing preclinical development of its ORY-2001 ...
Breaking Medicine Technology:New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... to Educate Women About this Common Condition, MILWAUKEE, ... at the Hyatt Regency Milwaukee hotel (333 West Kilbourn ... 7:30 pm to talk about her,experience with stress urinary ... Down There?: Breaking the Ice About SUI, a,national public ...
... Opiate-Like Side Effects For Several ... Months Following a Single Administration, SOUTH SAN FRANCISCO, Calif., ... that it has initiated a new,Phase 2 study of Adlea(TM) ... total knee replacement surgery, also called,total knee arthroplasty (TKA). Adlea ...
Cached Medicine Technology:Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 2Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 2Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 4
(Date:8/27/2015)... Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... Association and the American Heart Association have released new guidelines to educate doctors and ... the last update to these particular guidelines came in 2007, so the new version ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Thriveology Founders, ... the featured speakers at The Amazing Aging Expo in Denver, Colorado on Saturday, August ... doctors are consistently featured in media outlets as health authorities, and will present a ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... the exploding legal marijuana industry with the launch of its Doobster platform, a ... marijuana to order products from their smart phones and tablets. Well, Doobster, ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of mothers ... Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and causing ... University study. , While most people don’t develop persistent depression after a major ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to ... a cutting-edge, noninvasive procedure to improve submental fat. The first and only Food ... without surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., ...
Breaking Medicine News(10 mins):Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
... ... in Ophthalmology (JCAHPO), and the Association of Technical Personnel in Ophthalmology (ATPO) proudly launched ... Reference Guide for the Ophthalmic Technician. , ... St. Paul, MN (Vocus) November 10, 2009 -- Compact, ...
... HATBORO, Pa., Nov. 10 InfoLogix, Inc. (Nasdaq: ... solutions for the healthcare and commercial industries, today announced ... exception to NASDAQ,s stockholder approval requirements, in accordance with ... on this exception to complete a proposed plan of ...
... ... Arm in the Last 30 Years" , ... Gulf Breeze, Fla. (Vocus) November 10, 2009 -- The Andrews-Paulos Research & ... Rounds presentation on November, 19, 2009 at 5:30 p.m. (CT). Renowned orthopaedic and sports ...
... Better coordination urged to stem re-admission rate of nearly 1 ... Almost a quarter of the people on Medicare who are ... a month of discharge, a new study reveals. , That ... assistant professor of geriatrics and palliative medicine at the Mount ...
... YORK Medications frequently given to cancer patients to ... increased risk of deep vein thrombosis or pulmonary embolism, ... M.S., co-director of the breast cancer program at the ... Medical Center. The findings will be published online on ...
... Amalgamated Capital, a newly formed division of Amalgamated ... in the recapitalization of Oklahoma City-based 180 Medical, Inc., ... Amalgamated Capital provides senior cash flow debt financing to ... firms and other investors are financial sponsors. , 180 ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 4Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 5Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3Health News:The Revolving Door of Heart Failure Hospitalization 2Health News:The Revolving Door of Heart Failure Hospitalization 3Health News:Drugs to treat anemia in cancer patients linked to thromboembolism 2Health News:Drugs to treat anemia in cancer patients linked to thromboembolism 3Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 2Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 3Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: